FDA Approves First Venous Stent for Deep Venous Disease in IVC and Iliofemoral Veins
Key Insights
W.L. Gore & Associates (search) received FDA approval for the Gore Viabahn Fortegra Venous Stent (search), the first device specifically indicated for treating deep venous disease (search) in the inferior vena cava (search), iliac and iliofemoral veins (search).
The device achieved 83.4% primary patency at 12 months in a clinical trial of 89 patients with extensive thrombotic disease (search), with regional patency rates reaching 96.5% in the IVC.
The stent features an open-structure, self-expanding nitinol frame with polymer lattice designed for conformability and compression resistance, with no device-related deaths or stent fractures reported.
W.L. Gore & Associates (search) has achieved a significant regulatory milestone with FDA approval of the Gore Viabahn Fortegra Venous Stent (search), marking the first device specifically indicated for treating deep venous disease (search) in the inferior vena cava (search) (IVC), iliac and iliofemoral veins (search). The device, formerly known as the Gore Viafort Vascular Stent, represents a breakthrough in addressing some of the most challenging venous obstructive pathologies.
Device Design and Engineering
The Fortegra Venous Stent features an innovative open-structure, self-expanding wire-wound nitinol frame combined with an expanded polytetrafluoroethylene (ePTFE) polymer lattice. This design is specifically engineered to provide an optimal balance of conformability and compression resistance, allowing the stent to conform to natural anatomy while maintaining structural integrity throughout the entire device. The device is available in a wide range of sizes to accommodate varying patient anatomies.
According to Kush Desai, MD, the National Primary Investigator, "The FORTEGRA Venous Stent represents a significant advancement in the treatment of patients with the most difficult-to-treat venous obstructive pathology (search); occlusion of the inferior vena cava (search), iliac veins (search) and inflow femoral veins. Patients will benefit from a device that is designed specifically for this disease and its unique anatomic and physiologic challenges, including preservation of optimal flow dynamics through iliocaval confluence and side branch preservation."
Clinical Trial Results
The device's approval was supported by an international clinical trial that marked the first prospective study of its kind to include IVC, iliac and iliofemoral veins (search). The study enrolled 89 patients with extensive disease burden, demonstrating the device's safety and efficacy in a challenging patient population.
Patient Population Characteristics
The trial included patients with significant disease complexity: all participants were treated for thrombotic disease (search), including acute, subacute and post-thrombotic syndrome (search) cases. Notably, 94.3% of patients had lesions spanning three vessel regions (IVC plus bilateral iliofemoral veins (search)), and 68.5% required stents extending below the inguinal ligament into the common femoral vein.
Efficacy Outcomes
Despite the extensive disease burden in the study population, the Fortegra Venous Stent achieved impressive patency rates. The primary endpoint of 12-month primary patency was reached in 83.4% of patients. Regional analysis revealed even more encouraging results, with primary patency rates of 96.5% in the IVC, 88.9% in the left iliofemoral vein, and 89.8% in the right iliofemoral vein.
Safety Profile
The safety profile of the device was notably strong throughout the 12-month follow-up period. The trial reported no stent embolizations, migrations, fractures, vascular injuries, or clinically significant pulmonary embolisms. Additionally, there were no device-related deaths or major bleeding events through 30 days, and no device-related deaths were reported throughout the entire study period.
Regulatory Recognition
The Fortegra Venous Stent received Breakthrough Device designation from the FDA, a program designed to expedite the development and review of medical devices that offer more effective treatment for life-threatening or irreversibly debilitating diseases or conditions. The device successfully met its 12-month composite efficacy and safety primary endpoint, supporting its regulatory approval.
Clinical Impact
The approval addresses a significant unmet need in treating deep venous disease (search) affecting the IVC and iliofemoral vessels. The device's specific engineering for conformability, strength, and fracture resistance makes it particularly suitable for the unique anatomic and physiologic challenges presented by these vessel regions.
The Fortegra Venous Stent joins Gore's extensive portfolio of medical devices, backed by over 55 million implanted devices across 50 years of medical innovation. This approval represents a significant advancement for patients with complex venous obstructive pathology (search), offering a purpose-built solution for previously difficult-to-treat conditions.